| 1 |
32095692 | Nicotinamide-Ponatinib Analogues as Potent Anti-CML and Anti-AML Compounds. | 2020 Feb 18 |
1 |
| 2 |
33194747 | Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. | 2020 |
1 |
| 3 |
25053825 | BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. | 2014 Oct |
2 |
| 4 |
23430109 | Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. | 2013 Apr 18 |
4 |
| 5 |
22409268 | Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. | 2012 May |
7 |
| 6 |
22778153 | The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. | 2012 Sep |
2 |
| 7 |
21482694 | Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. | 2011 Jun |
6 |